Table 3.
Proportion of women (cumulative) with plasma and RBC folate levels below the mean median baseline value, and with homocysteine levels above the mean median baseline value in the 20-week period following the cessation of 24 weeks of treatment with EE-drospirenone-levomefolate calcium or EE-drospirenone + folic acid (per protocol set)
| Week | Plasma folate
|
RBC folate
|
Homocysteine
|
|||
|---|---|---|---|---|---|---|
| Levomefolate calcium | Folic acid | Levomefolate calcium | Folic acid | Levomefolate calcium | Folic acid | |
| 26 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (5.3) | 2 (2.7) |
| 28 | 4 (5.3) | 4 (5.3) | 0 (0.0) | 0 (0.0) | 8 (10.7) | 5 (6.7) |
| 30 | 5 (6.7) | 8 (10.7) | 0 (0.0) | 0 (0.0) | 11 (14.7) | 9 (12.0) |
| 32 | 11 (14.7) | 12 (16.0) | 0 (0.0) | 0 (0.0) | 14 (18.7) | 12 (16.0) |
| 34 | 15 (20.0) | 17 (22.7) | 1 (1.3) | 0 (0.0) | 16 (21.3) | 14 (18.7) |
| 36 | 23 (30.7) | 23 (30.7) | 2 (2.7) | 2 (2.7) | 19 (25.3) | 17 (22.7) |
| 38 | 25 (33.3) | 25 (33.3) | 2 (2.7) | 2 (2.7) | 20 (26.7) | 23 (30.7) |
| 40 | 30 (40.0) | 34 (45.3) | 6 (8.0) | 2 (2.7) | 22 (29.3) | 26 (34.7) |
| 42 | 30 (40.0) | 38 (50.7) | 7 (9.3) | 3 (4.0) | 25 (33.3) | 29 (38.7) |
| 44 | 44 (58.7) | 45 (60.0) | 8 (10.7) | 6 (8.0) | 26 (34.7) | 30 (40.0) |
Notes: Data are n (%). The mean median baseline values were as follows for EE-drospirenone-levomefolate calcium and EE-drospirenone + folic acid, respectively: plasma folate, 16.4 and 14.1 nmol/L; RBC folate, 578.3 and 550.2 nmol/L; homocysteine, 9.3 and 9.2 μmol/L.
Abbreviations: EE, ethinylestradiol; RBC, red blood cells.